Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 14, 2019; 25(34): 5082-5096
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5082
Table 2 Main characteristics of high-risk individuals for pancreatic cancer in the different studies
First author/yrSettingHigh risk conditionPatients includedModalities of screeningImaging resultsPatients operated onOperated lesions seen only by the EUSHistological features with cancer or HGD
Brentnall et al[37]Prospective, monocentricFPC14EUSCPis: 10 (77%) Cystic lesio: ? Solid lesio: 6 (46%)71NA7 dysplasia
Rulyak et al[38]Prospective, monocentricFPC35EUS, ERCP12 lesions12?12 dysplasia
Kimmey et al[78]Prospective, monocentricFPC46EUS, ERCPCPis: 24 (52%) Cystic lesion: ? Solid lesion: 12 (26%)???
Canto et al[12]Prospective, monocentricFPC, PJS,38EUS first, +/- ERCP, CT, FNACPis: 17 (45%) Cystic lesion: ? Solid lesion: 12 (31%)72/7 (1 PC, 1 PanIN3)1 PC 1 PanIN3
Canto et al[23]Prospective, monocentricFPC, PJS,78EUS, CT +/- ERCP, FNACPis: 61 (78%) Cystic lesion: 9 (12%) Solid lesion: 8 (10%)73/7 (1 PanIN 3, 2 PanIN1-2)1 PC+IPMN 1 PanIN3 1PanIN3+IPMN
Poley et al[13]Prospective, multicentricFPC, PJS, FAMMM, FBOC, HP, LFS44EUSCPis: 3 (7%) Cystic lesion: 7 (16%) Solid lesion: 3 (7%)101NA3 PC
Langer et al[15]Prospective, multicentricFPC, FAMMM76EUS + MRICPis: 17 (22%) Cystic lesion: 3 (4%) Solid lesion: 7 (9%)75/7 (9/21 non operated lesions seen only in EUS)0 PC or PanIN3 or IPMN with HGD
Verna et al[33]Prospective, monocentricFPC, FBOC51EUS n = 31 or MRI n = 33 +/- ERCP, FNACPis: 9 (29%) Cystic lesion: 12 (39%) Solid lesion: 2 (6%)5? (2 solid lesions in EUS and MRI)1 PC 1 PanIN2
Ludwig et al[34]Prospective, monocentricFPC109MRCP or CT EUS, FNA18 lesions6?1 PC 2 MD IPMN 1 PanIN-3 1 PanIN-2
Schneider et al[40]Prospective, monocentricFPC, FAMMM72EUS, MRI13 lesions9?1 PC 1 PanIN-3
Zubarik et al[16]Prospective, monocentricFPC, PJS, BRCA227CA19-9 +/- EUS (27/546)5 lesions51NA1 PC
Canto et al[25]Prospective, multicentricFPC, FBOC, PJS216CT, EUS, MRI/MRCPCPis: 54 (25%) Cystic lesion: 79 (36%) Solid lesion: 3 (1.4%)5? (20/216 non operated lesions seen only in EUS including 3 solid lesion)2 MD-IPMN 1 IPMN+PanIN3
Al-Sukhni et al[32]Prospective, monocentricFPC, BRCA1/2, FAMMM, LKB1252MRI, +/- CT, EUS, ERCPCPis: ? Cystic lesion: 80 (32%) Solid lesion: 3 (1.2%)43 PC
Sud et al[14]Prospective, monocentricFPC, BRCA1/2, MMR, CDKN2A, LKB1, PRSS130EUS +/- FNA3 lesions31NA2 PC
Mocci et al[10]Prospective, multicentricFPC, CDKN2A, MMR, PRSS141EUS, CT +/- MRI, FNACPis: 15 (37%) Cystic lesion:4 (10%) Solid lesion: 2 (5%)12NA1 NET 1 PanIN3
Vasen et al[31]Prospective, multicentricFPC, CDKN2A, BRCA 1/2411MRI, EUS, CT, FNACPis: ? Cystic lesion: 138 (34%) Solid lesion: 16 (4%)302/30 (866 MRIs and 106 EUS performed)16 PC 3 PanIN3 1 IPMN with high grade
Bartsch et al[4]Prospective, multicentricFPC, BRCA1/2, PALB2234MRI, EUS, CT, FNACPis: ? Cystic lesion: 125 (49%) Solid lesion: 9 (4%)21 6/253 (2%) lesions (2 malignant and HGD)?2 PC 3 PanIN3 1 IPMN with HGD; multifocal PanIN2±BD-IPMN±AFL 1 NET 8 PanIN-2
Harinck et al[27]Prospective, multicentricFPC, BRCA1/2, CDKN2A, LKB1, TP53, MMR139MRI +/- EUSCPis: 41 (30%) Cystic lesion: 67 (48%) Solid lesion: 2 (1.4%)22/2 (1 PC, 1 PanIN-2)1 PC 1 PanIN-2